Takeda Options Potential Iclusig Successor In Ascentage Deal

 
• By Dexter Jie Yan

Takeda has signed an option deal for Ascentage's olverembatinib, being investigated in two global Phase III trials in the same leukemia indications as those for the Japanese firm's existing drug Iclusig. Olverembatinib has also shown potential to overcome resistance to Iclusig and global competitor Novartis's Scemblix.

succession
Takeda and Ascentage's option and share investment deals hinge on a potential successor to Iclusig. • Source: Shutterstock

More from China

More from Focus On Asia